Payment overview · 2025
General Payments
$3,910.11
148 reported records · 17 companies
Healthcare provider profile · identity verified
Thomas Gregory Mckelvey, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MOBILE, AL · NPI 1306844394
Verified facts
What the public records show
CMS Open Payments records show Thomas Gregory Mckelvey, MD received $3,910.11 in general payments during 2025 across 148 reported records.
Novo Nordisk Inc accounted for 58.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance, Kerendia, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta, Ubrelvy, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 430 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 299 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 299 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 434 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 619 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $2,301.56 | 58.9% | 32 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $397.32 | 10.2% | 48 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $220.83 | 5.7% | 8 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $172.48 | 4.4% | 9 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $161.33 | 4.1% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $157.12 | 4.0% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $125.21 | 3.2% | 9 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $66.85 | 1.7% | 4 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $63.76 | 1.6% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $54.43 | 1.4% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $46.06 | 1.2% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $45.92 | 1.2% | 4 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $24.07 | 0.6% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $20.50 | 0.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.74 | 0.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.31 | 0.4% | 1 | 2025 |
| Rhythm Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.62 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,032.67 | 146 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,877.44 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $2,136.01 | 13 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $363.39 | 41 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $272.77 | 39 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $220.83 | 8 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $172.48 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $165.55 | 19 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $163.96 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $161.33 | 11 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $142.46 | 15 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $90.90 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $88.22 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $75.12 | 5 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $66.85 | 4 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $63.76 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $50.59 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $45.92 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $37.38 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $34.31 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $30.77 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $27.49 | 6 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $24.07 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $20.50 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.74 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.05 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.05 | 1 | 2025 |
Source payment records
|
|||||
| IMCIVREE Normalized: imcivree |
Drug | Rhythm Pharmaceuticals, Inc. | $15.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 430 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 299 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 434 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 619 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 45 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
38 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
44 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
430 | 122 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
299 | 75 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
45 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
299 | 75 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
434 | 73 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
619 | 162 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
37 | 12 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1206 | 374 |
| Ezetimibe | Ezetimibe | 1046 | 323 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 884 | 265 |
| Amlodipine Besylate | Amlodipine Besylate | 670 | 208 |
| Valsartan | Valsartan | 634 | 193 |
| Ozempic | Semaglutide | 619 | 162 |
| Famotidine | Famotidine | 575 | 180 |
| Levothyroxine Sodium | Levothyroxine Sodium | 571 | 156 |
| Metformin Hcl Er | Metformin Hcl | 548 | 189 |
| Mounjaro | Tirzepatide | 434 | 73 |
| Farxiga | Dapagliflozin Propanediol | 430 | 122 |
| Omeprazole | Omeprazole | 426 | 132 |
| Irbesartan | Irbesartan | 360 | 104 |
| Pantoprazole Sodium | Pantoprazole Sodium | 358 | 123 |
| Losartan Potassium | Losartan Potassium | 334 | 106 |
| Trazodone Hcl | Trazodone Hcl | 308 | 92 |
| Jardiance | Empagliflozin | 299 | 75 |
| Gabapentin | Gabapentin | 292 | 108 |
| Carvedilol | Carvedilol | 275 | 89 |
| Zolpidem Tartrate | Zolpidem Tartrate | 275 | 53 |
| Spironolactone | Spironolactone | 270 | 89 |
| Furosemide | Furosemide | 256 | 100 |
| Bupropion Xl | Bupropion Hcl | 231 | 70 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 220 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 215 | 71 |
| Hydrochlorothiazide | Hydrochlorothiazide | 205 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 205 | 73 |
| Escitalopram Oxalate | Escitalopram Oxalate | 196 | 62 |
| Duloxetine Hcl | Duloxetine Hcl | 193 | 59 |
| Montelukast Sodium | Montelukast Sodium | 192 | 65 |
| Tizanidine Hcl | Tizanidine Hcl | 176 | 64 |
| Meloxicam | Meloxicam | 170 | 66 |
| Pioglitazone Hcl | Pioglitazone Hcl | 165 | 55 |
| Lisinopril | Lisinopril | 161 | 47 |
| Allopurinol | Allopurinol | 142 | 47 |
| Potassium Chloride | Potassium Chloride | 135 | 46 |
| Ibandronate Sodium | Ibandronate Sodium | 129 | 49 |
| Buspirone Hcl | Buspirone Hcl | 120 | 43 |
| Fluconazole | Fluconazole | 119 | 65 |
| Repatha Sureclick | Evolocumab | 119 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 116 | 39 |
| Metformin Hcl | Metformin Hcl | 114 | 35 |
| Doxepin Hcl | Doxepin Hcl | 106 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 103 | 34 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 99 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 85 | 29 |
| Januvia | Sitagliptin Phosphate | 79 | 21 |
| Sertraline Hcl | Sertraline Hcl | 78 | 24 |
| Celecoxib | Celecoxib | 77 | 31 |
| Clonazepam | Clonazepam | 77 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 75 | 30 |
| Tresiba Flextouch U-100 | Insulin Degludec | 75 | 33 |
| Tresiba Flextouch U-200 | Insulin Degludec | 74 | 26 |
| Mirtazapine | Mirtazapine | 69 | 29 |
| Diclofenac Sodium | Diclofenac Sodium | 66 | 25 |
| Donepezil Hcl | Donepezil Hcl | 66 | 23 |
| Ipratropium Bromide | Ipratropium Bromide | 66 | 23 |
| Xarelto | Rivaroxaban | 66 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 64 | 23 |
| Vascepa | Icosapent Ethyl | 62 | 15 |
| Labetalol Hcl | Labetalol Hcl | 61 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 60 | 22 |
| Valacyclovir | Valacyclovir Hcl | 60 | 28 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 58 | 29 |
| Mupirocin | Mupirocin | 56 | 27 |
| Topiramate | Topiramate | 56 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 55 | 17 |
| Nebivolol Hcl | Nebivolol Hcl | 55 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | 16 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 53 | 20 |
| Aliskiren | Aliskiren Hemifumarate | 52 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 50 | 15 |
| Pregabalin | Pregabalin | 50 | 17 |
| Cephalexin | Cephalexin | 49 | 39 |
| Memantine Hcl | Memantine Hcl | 48 | 20 |
| Humalog Kwikpen U-100 | Insulin Lispro | 47 | 16 |
| Solifenacin Succinate | Solifenacin Succinate | 47 | 17 |
| Entresto | Sacubitril/Valsartan | 45 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | 13 |
| Icosapent Ethyl | Icosapent Ethyl | 44 | 15 |
| Synthroid | Levothyroxine Sodium | 44 | 17 |
| Fenofibrate | Fenofibrate | 42 | 12 |
| Primidone | Primidone | 42 | 13 |
| Trulicity | Dulaglutide | 42 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 41 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 40 | 22 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 38 | 14 |
| Linzess | Linaclotide | 38 | 13 |
| Eliquis | Apixaban | 37 | 12 |
| Finasteride | Finasteride | 37 | 14 |
| Myrbetriq | Mirabegron | 37 | 13 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 37 | 13 |
| Dapagliflozin | Dapagliflozin Propanediol | 36 | 20 |
| Doxazosin Mesylate | Doxazosin Mesylate | 36 | suppressed |
| Ondansetron Odt | Ondansetron | 36 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 11 |
| Alendronate Sodium | Alendronate Sodium | 34 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 34 | suppressed |
| Kerendia | Finerenone | 34 | suppressed |
| Telmisartan | Telmisartan | 34 | 11 |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Rybelsus | Semaglutide | 33 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | 11 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 29 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 29 | suppressed |
| Chlorthalidone | Chlorthalidone | 28 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | 13 |
| Novolog Flexpen | Insulin Aspart | 28 | 11 |
| Tramadol Hcl | Tramadol Hcl | 28 | 18 |
| Gemtesa | Vibegron | 27 | suppressed |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 27 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | 11 |
| Atenolol | Atenolol | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 26 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 26 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 23 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 23 | suppressed |
| Colchicine | Colchicine | 22 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Cefdinir | Cefdinir | 20 | 18 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 20 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Febuxostat | Febuxostat | 20 | suppressed |
| Metolazone | Metolazone | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Testosterone | Testosterone | 18 | suppressed |
| Alprazolam | Alprazolam | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 16 |
| Methimazole | Methimazole | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Simvastatin | Simvastatin | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 11 |
| Anastrozole | Anastrozole | 15 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 15 | suppressed |
| Invokamet Xr | Canagliflozin/Metformin Hcl | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Trospium Chloride | Trospium Chloride | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 13 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 13 | suppressed |
| Wegovy | Semaglutide | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Edarbi | Azilsartan Medoxomil | 12 | suppressed |
| Gvoke Hypopen 2-Pack | Glucagon | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | 11 |
| Invokana | Canagliflozin | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 11 |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Ubrelvy | Ubrogepant | 12 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 11 | suppressed |
| Ambien Cr | Zolpidem Tartrate | 11 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,910.11 · 148 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, AREXVY, COMIRNATY, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, GVOKE HYPOPEN, IMCIVREE, JARDIANCE, KISUNLA, Kerendia, MOUNJARO, NEXLETOL, OTEZLA, Omnipod, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, Wegovy, XIFAXAN, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error